Jyotsna Bhatt1, Archana Mukherjee2, Aruna Korde1, Mukesh Kumar3, Haladhar Dev Sarma4, Ashutosh Dash1. 1. Radiopharmaceuticals Evaluation Section, Isotope Production & Applications Division, Bhabha Atomic Research Centre, Mumbai, 400 085, India. 2. Radiopharmaceuticals Evaluation Section, Isotope Production & Applications Division, Bhabha Atomic Research Centre, Mumbai, 400 085, India. archanas@barc.gov.in. 3. Solid State Physics Division, Bhabha Atomic Research Centre (BARC), Mumbai, 400 085, India. 4. Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre (BARC), Mumbai, 400 085, India.
Abstract
PURPOSE: The present work was aimed at the development of prospective positron emission tomography (PET) agents for infection imaging. Towards this aim, ubiquicidin (UBI) fragments conjugated with the macrocyclic NODAGA chelator were radiolabeled with Ga-68 and evaluated. PROCEDURES: Conformations of custom synthesized NODAGA-UBI (29-41) and NODAGA-UBI (31-38) conjugates were compared with UBI (29-41) by circular dichroism (CD) spectroscopy. Optimization of labeling of NODAGA conjugates of UBI peptides with Ga-68 was performed and quality control analysis was carried out by chromatography techniques. In vitro uptake of [68Ga] NODAGA-UBI (29-41) and [68Ga]NODAGA-UBI (31-38) was studied in Staphylococcus aureus cells. In vivo distribution of [68Ga]GaCl3 and [68Ga]NODAGA-UBI complexes was performed in normal Swiss mice. RESULTS: Conformations of NODAGA-UBI (29-41) and NODAGA-UBI (31-38) conjugates were found to be similar to UBI (29-41). NODAGA-UBI conjugates could be consistently labeled with Ga-68 in high radiochemical yields (>95 %) with high radiochemical purity (>95 %). [68Ga]NODAGA-UBI (29-41) and [68Ga]NODAGA-UBI (31-38) complexes showed retention time of 14 and 14.5 min, respectively, by HPLC radiochromatogram. Specific uptake of [68Ga]NODAGA-UBI fragments was observed in S.aureus cells. Greater than 64 % of the injected dose was cleared via the renal route at 1 h post injection, and no significant uptake in vital organs of mice was observed with both the agents. CONCLUSION: This is the first report on Ga-68 labeled NODAGA-UBI fragments for infection imaging and the agents hold tremendous prospect in PET imaging.
PURPOSE: The present work was aimed at the development of prospective positron emission tomography (PET) agents for infection imaging. Towards this aim, ubiquicidin (UBI) fragments conjugated with the macrocyclic NODAGA chelator were radiolabeled with Ga-68 and evaluated. PROCEDURES: Conformations of custom synthesized NODAGA-UBI (29-41) and NODAGA-UBI (31-38) conjugates were compared with UBI (29-41) by circular dichroism (CD) spectroscopy. Optimization of labeling of NODAGA conjugates of UBI peptides with Ga-68 was performed and quality control analysis was carried out by chromatography techniques. In vitro uptake of [68Ga] NODAGA-UBI (29-41) and [68Ga]NODAGA-UBI (31-38) was studied in Staphylococcus aureus cells. In vivo distribution of [68Ga]GaCl3 and [68Ga]NODAGA-UBI complexes was performed in normal Swiss mice. RESULTS: Conformations of NODAGA-UBI (29-41) and NODAGA-UBI (31-38) conjugates were found to be similar to UBI (29-41). NODAGA-UBI conjugates could be consistently labeled with Ga-68 in high radiochemical yields (>95 %) with high radiochemical purity (>95 %). [68Ga]NODAGA-UBI (29-41) and [68Ga]NODAGA-UBI (31-38) complexes showed retention time of 14 and 14.5 min, respectively, by HPLC radiochromatogram. Specific uptake of [68Ga]NODAGA-UBI fragments was observed in S.aureus cells. Greater than 64 % of the injected dose was cleared via the renal route at 1 h post injection, and no significant uptake in vital organs of mice was observed with both the agents. CONCLUSION: This is the first report on Ga-68 labeled NODAGA-UBI fragments for infection imaging and the agents hold tremendous prospect in PET imaging.
Authors: Thomas Ebenhan; Nicholas Chadwick; Mike M Sathekge; Patrick Govender; Thavendran Govender; Hendrik G Kruger; Biljana Marjanovic-Painter; Jan Rijn Zeevaart Journal: Nucl Med Biol Date: 2014-02-13 Impact factor: 2.408
Authors: M M Welling; A Lupetti; H S Balter; S Lanzzeri; B Souto; A M Rey; E O Savio; A Paulusma-Annema; E K Pauwels; P H Nibbering Journal: J Nucl Med Date: 2001-05 Impact factor: 10.057
Authors: P H Nibbering; M M Welling; P J van den Broek; K E van Wyngaarden; E K Pauwels; W Calame Journal: Nucl Med Commun Date: 1998-12 Impact factor: 1.690
Authors: Peter H Nibbering; Mick M Welling; Akke Paulusma-Annema; Carlo P J M Brouwer; Antonella Lupetti; Ernest K J Pauwels Journal: J Nucl Med Date: 2004-02 Impact factor: 10.057